Happy Mother’s Day to all the Mushroom Moms out there! I figured today would be a perfect day to talk about moms who microdose.—Nate
This year, Americans will spend roughly $38 billion on Mother’s Day gifts including flowers, brunches, spa gift cards, and the classic card with something about strength and sacrifice.
What that $35 billion does not buy is any serious infrastructure for maternal mental health. As many as one in seven mothers will experience postpartum depression. Rates of anxiety among mothers of young children have increased steadily for a decade. The standard clinical response of SSRIs, a six-week postpartum check-in, and a referral to a therapist with a three-month waitlist, has not meaningfully changed in thirty years.
A bit of history
Before modern clinical trials, there were curanderas—traditional healers in Latin American and Indigenous Mesoamerican cultures (primarily women) who used plants, fungi, rituals, and spiritual practices to treat physical, emotional, and community illnesses. These women were doctors, therapists, midwives, and spiritual guides all in one. In Mesoamerica, psilocybin mushrooms were used ceremonially for centuries, and the keepers of that knowledge were often women. Maria Sabina, the Mazatec healer who introduced psilocybin to Western consciousness in the 1950s, was a mother who had been conducting healing ceremonies for decades before a banker and amateur mycologist named R. Gordon Wasson showed up and wrote about it in Life magazine—without her consent and against his promise of secrecy. The Mazatec indigenous communities who stewarded these traditions for millennia hold none of the patents that have since been filed on psilocybin compounds…
In many parts of Europe, the women who worked with plant medicines like ergot, henbane, mandrake, and fungi were not celebrated. Many were tried as witches. As documented in the medical history of ergot and in historical research on women healers persecuted by the Inquisition, midwives in Western Europe regularly used ergot (a fungus and the precursor to LSD) during labor, at a time when the Church held that pain in childbirth was divine punishment and any attempt to ease it was heresy. The systematic persecution of herbalists and midwives between the 14th and 17th centuries attempted to smother a tradition of female healing knowledge that had accumulated over generations. What survived went underground, passed person to person, family to family, outside the institutions that were burning it.
The mothers microdosing in private online communities in 2026 are doing something very old, in a new context, for the same reasons women always have: because the official system was not built for them, and they forged their own way.
On community
There is a private online community called Moms on Mushrooms (M.O.M.) with over 3,700 members across more than 40 countries. Membership costs $2 a month, and the subject at hand is microdosing psilocybin: taking sub-perceptual doses every few days to manage anxiety, emotional reactivity, mental load, identity loss, ADHD, and perimenopause in order to function better, feel more present, and in many cases, feel like themselves again.
It was founded by Colorado-based comedian and entrepreneur Tracey Tee, who discovered microdosing after a full hysterectomy triggered sudden surgical menopause. She had tried an antidepressant and it didn’t produce the internal shift she was looking for. But psilocybin did.
“I just really felt a calm and a space between my world that I hadn’t felt before,” she has said. She felt strongly enough about it to build a formal education and integration platform around it, with trained facilitators and cohorts of three to six women.
M.O.M. is a very visible branch of a much larger, loosely organized network of mothers using psilocybin outside clinical settings and building their own harm reduction infrastructure to do it responsibly.
What they’re using it for
The entry-level description of microdosing is well established at this point: roughly one-tenth to one-twentieth of a full psychedelic dose, taken on a rotating schedule, producing no hallucinations and minimal perceptible alteration. The reported effects of reduced anxiety, improved emotional regulation, and greater presence, are the same ones showing up in naturalistic research.
A 2021 study published in Scientific Reports tracking over 4,000 microdosers found that health and wellness motivations like managing anxiety, improving mood, and feeling more present were the most prominent drivers across all microdosers, and were even more pronounced among women.
For mothers specifically, the interest clusters around a few overlapping problems:
1. The mental load
The invisible, unreciprocated cognitive and emotional labor of running a household—appointments, school forms, the emotional temperature of every person in the room, etc.—is relentless and rarely treated as a medical issue. Women in microdosing communities describe psilocybin as creating space between stimulus and response; less reactivity and more patience.
One member described it as making her “10% of something: 10% happier, 10% more patient, 10% more creative.”
2. Identity loss
There is a word for the psychological transformation of becoming a mother: matrescence. Coined by anthropologist Dana Raphael in the 1970s and developed more recently by clinical psychologist Aurelie Athan at Columbia University, it describes a reorganization of identity as significant as adolescence and is almost entirely unrecognized by medicine. Mothers in these communities frequently describe psilocybin as a way back to parts of themselves that caregiving had buried: creativity, curiosity, humor, sensuality. This maps, at least directionally, onto what full-dose psilocybin research describes as its core mechanism: reduced default mode network activity, increased neural connectivity, loosened top-down cognitive control. Whether those mechanisms operate meaningfully at sub-perceptual doses is, as we'll get to, still an open question.
Kate, a mother of two, put it this way when I asked what the hardest part of motherhood is for her:
“I guess there’s a level of isolation I didn’t anticipate. I think I felt like we’d all be goddesses floating around in gorgeous gowns with clean hair. But in fact we’re just feeling our way around in the dark and we periodically bump into each other and it’s amazing and so much knowledge is shared, but it’s not glamorous—it’s survival.”
3. ADHD and perimenopause
A 2024 review in the European Journal of Psychiatry by Maastricht University researcher K.P. Kuypers reported that, in a naturalistic study of adults with ADHD over a four-week microdosing protocol, participants showed reduced symptoms, increased trait mindfulness, and decreased neuroticism compared to baseline. A clinical trial followed, and data analysis is ongoing. ADHD in women is dramatically under-diagnosed. Many receive a first diagnosis in adulthood, often after their child does. Managing an ADHD brain while running a household is its own category of difficulty. If microdosing modulates attention and emotional dysregulation even modestly, that has real implications for a population the psychiatric system has historically missed.
The perimenopause angle is similarly under-explored. Hormonal fluctuations in a woman’s late 30s and 40s can destabilize mood, sleep, and cognition in ways that are frequently dismissed.
On the research
The most rigorous recent work on microdosing is more complicated than the community accounts suggest. A 2025 meta-analysis of 14 controlled studies across over 1,600 participants found no overall cognitive enhancement from microdosing, but did detect a meaningful reduction in cognitive rigidity; a loosening of top-down mental control that may enable more associative, flexible thinking. Three double-blind placebo-controlled trials found a real, if subtle, improvement in divergent thinking tasks. A large 2022 observational study from the University of British Columbia tracked 953 psilocybin microdosers over 30 days and found small to medium improvements in mood and mental health, consistent across gender, age, and presence of mental health concerns.
A 2024 rapid review by Vince Polito and Paul Liknaitzky examined whether microdosing effects might be mostly placebo. Their conclusion: probably not entirely. Some effects on mood, subjective experience, certain aspects of consciousness do show up under controlled conditions. Effects on cognition are less consistent. The most honest summary of the current evidence base is that microdosing appears to do something real but variable, and the effect sizes are modest.
The risks deserve equal clarity because psilocybin is not universally calming. In some individuals, particularly those with underlying trauma or certain psychiatric histories, it can increase anxiety rather than reduce it. The NCCIH flags insomnia, mood instability, GI symptoms, and impaired social functioning as documented adverse effects in some people. It is contraindicated for anyone with personal or family history of psychotic disorders, severe bipolar disorder, or borderline personality disorder. And a practical concern that rarely makes it into wellness content: measuring an accurate microdose outside a laboratory is genuinely difficult.
A 2025 animal model study out of UC Davis found that psilocybin actually increased anxiety and depressive symptoms during the postpartum period specifically, so that’s a reminder that hormonally sensitive windows may not respond the way the general literature predicts. The community is ahead of the science on the anecdotal side, but some of the risks are still not fully understood.
Citizen science
What’s notable about M.O.M. and communities like it is not just the scale but the structure. These are moderated forums. M.O.M. runs educational cohorts with trained facilitators and integration support. Mothers of the Mushroom (MOTM), a citizen science initiative led by psychedelic doula Mikaela de la Myco, has gathered survey data from nearly 400 mothers on psilocybin use across the full perinatal period from pre-conception, pregnancy, breastfeeding, and postpartum, in collaboration with microdosing researchers James Fadiman and Jordan Gruber. They cannot draw clinical conclusions from this data, but they are doing it anyway because the clinical data does not exist, and they decided that community-level evidence is better than nothing.
Legality
Psilocybin remains Schedule I at the federal level. Colorado and Oregon have moved toward regulated therapeutic access. Several cities have decriminalized personal possession. The Trump executive order signed in April 2026 accelerates FDA review timelines for clinical psilocybin and ibogaine, directs $50 million through ARPA-H to match state research investments, and establishes a pathway for investigational drug access under the Right to Try Act. It doesn’t legalize anything, but the direction of travel has changed faster than almost anyone predicted three years ago.
What that means for the underground maternal psilocybin community is genuinely unclear. Regulated clinical access tends to arrive slowly, expensively, and with eligibility criteria that can be hard to navigate. The clinical pipeline will probably not solve the problem these communities are trying to solve, at least not on any timeline that matters to a mother who is struggling right now.
Functional mushrooms
Not every mother in these spaces is microdosing psilocybin—many start with functional mushrooms. These are legal, non-psychoactive species that have accumulated a serious body of preclinical research. For mothers navigating chronic stress, disrupted sleep, hormonal fluctuation, and cognitive fatigue, the three most relevant are perhaps reishi, lion’s mane, and cordyceps.
Reishi helps regulate cortisol levels and supports the adrenal glands, which play a central role in managing the body’s stress response. Research suggests reishi compounds may also influence estrogen and androgen metabolism, potentially helping to restore hormonal balance under chronic stress. Most people take it in the evening because it is calming, immune-modulating, and associated with improved sleep quality.
Lion’s mane contains compounds called hericenones and erinacines that stimulate nerve growth factor, a protein critical to the development and maintenance of neurons. A 2023 analysis found that lion’s mane helped boost cognition and energy in adults. For mothers dealing with the particular fog of sleep deprivation, hormonal shifts, and relentless context-switching, the appeal is straightforward.
Cordyceps may enhance oxygen usage and increase cellular energy production, potentially improving energy levels and reducing fatigue. It supports adrenal health, stamina, and oxygen use, making it useful for busy mornings or the general physical demands of keeping small humans alive.
A 2024 randomized double-blind placebo-controlled trial studying a blend of all three found observed benefits consistent with existing research on each: lion’s mane for cognitive and mood support, cordyceps for energy and metabolic regulation, reishi for calming and neuroendocrine balance. The research base is still building and most studies are preclinical or small-scale, but these are legal, widely available, and carry a meaningful history of traditional use that predates the wellness industry by centuries. For many mothers, they are a lower-stakes entry point into a much older relationship between women and fungi.
Growing your own mushrooms
Home cultivation of functional mushrooms like lion’s mane, reishi, oyster, shiitake is legal, accessible, and increasingly popular. Grow kits have made the process straightforward enough that it requires no prior knowledge and minimal equipment.
The usage of medicinal fungi was traditionally domestic knowledge, living in households, passed between women, and tied to the rhythms of seasons and family health. Growing your own may be a reclamation of that. You learn how mycelium behaves, how a healthy culture looks versus a degraded one, what conditions produce mushrooms and how to troubleshoot. It is slow, attentive work that runs counter to everything about the pace modern motherhood demands, and perhaps that is part of why people find it meaningful.
It is also a way to understand what you are consuming. The functional mushroom supplement market is crowded with products that vary in quality, potency, and whether they use the fruiting body or the mycelium. Growing your own removes that variable entirely and what comes out of the substrate is what goes into your body.
Final thoughts
The women in these online microdosing communities are operating on incomplete information in a space where the medical system has largely abandoned them, and making decisions that, for many of them, appear to be working.
That all said, context—set, setting, integration, support—are incredibly important in mitigating risks, and the women who have built communities around those elements understand that better than many clinicians do.
Functional mushrooms offer a legal, accessible, lower-stakes entry point into a relationship with fungi that has its own real evidence base and its own long history. Growing your own takes that further: it is slow, attentive work that puts you in direct relationship with the organism itself, outside the supply chain, outside the supplement market, outside the institutions that have alternately ignored and criminalized this knowledge for centuries.
While spa days and a mimosas are important, it’s worth understanding that maternal suffering has yet to be taken seriously enough as a priority in research. The mothers who found their way to psilocybin are taking their care into their own hands.
So if you’re a mom and feel for sharing, what do you do to feel more like yourself?
Nothing in this article constitutes medical advice. Psilocybin carries real risks and legal status varies by jurisdiction. Approach it within appropriate harm reduction frameworks.
References and further reading:
Mothers of the Mushroom — citizen science initiative & community data
Moms on Mushrooms — education & integration platform
Rootman et al. (2021). Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers. Scientific Reports
Rootman et al. (2022). Psilocybin microdosers demonstrate greater observed improvements in mood and mental health. Scientific Reports
Kuypers (2024). Microdosing psychedelics in the treatment of ADHD and comorbid disorders. European Journal of Psychiatry
Polito & Liknaitzky (2024). Is microdosing a placebo? Journal of Psychopharmacology
Dodd et al. (2023). The acute and chronic effects of lion’s mane mushroom supplementation on cognitive function, stress and mood in young adults. Nutrients
Hatzipantelis et al. (2025). Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. Nature Communications
Athan (2024). A critical need for the concept of matrescence in perinatal psychiatry. Frontiers in Psychiatry
Szigeti et al. (2025). Psilocybin microdosing and cognitive function: a meta-analysis. Neuroscience & Biobehavioral Reviews
Trump White House (2026). Fact Sheet: Accelerating Medical Treatments for Serious Mental Illness.
NCCIH. Psilocybin for Mental Health and Addiction: What You Need to Know.
Thank you for sharing this article. The information here was very helpful, educational and non-inflammatory.